Effectiveness of second-dose varicella vaccination as post-exposure prophylaxis: a prospective cohort study

Clin Microbiol Infect. 2019 Jul;25(7):872-877. doi: 10.1016/j.cmi.2018.11.013. Epub 2018 Nov 23.

Abstract

Objectives: Although administration of a second dose of varicella vaccine (2nd-dose VarV) to individuals who have previously received one-dose VarV has been recommended as a post-exposure prophylaxis (PEP) strategy for outbreak control, the effectiveness of this strategy remains unclear. We evaluated the vaccine effectiveness (VE) of 2nd-dose VarV as PEP among students involved in 129 varicella outbreaks in Shanghai, China from 2013 to 2016.

Methods: Students who had received one-dose VarV more than 5 years prior to varicella exposure were eligible to receive 2nd-dose VarV as PEP. We evaluated the VE using the following formula: VE = (1 - hazard ratio (HR)) × 100%.

Results: A total of 6762 students were eligible for 2nd-dose VarV, of whom 58.6% accepted PEP after varicella exposure. The adjusted VE of 2nd-dose VarV as PEP was 77% (95% confidence interval 64-85%). In addition, the adjusted VE of 2nd-dose VarV as PEP in affected classrooms with high vaccine uptake was higher than that in classrooms with lower vaccine uptake (87% vs. 69%). The adjusted VE was also higher in students who received 2nd-dose VarV within 3 days of exposure than those who received it more than 3 days post exposure (77% vs. 64%).

Conclusions: These Results suggest that administration of 2nd-dose VarV as PEP is an appropriate intervention for outbreak control in countries where two-dose VarV has not been adopted.

Keywords: Outbreak; Post-exposure prophylaxis; Vaccine effectiveness aricella vaccine; Varicella; Varicella vaccine.

MeSH terms

  • Adolescent
  • Chickenpox / epidemiology
  • Chickenpox / prevention & control*
  • Chickenpox Vaccine / administration & dosage*
  • Child
  • China / epidemiology
  • Disease Outbreaks / prevention & control
  • Female
  • Herpesvirus 3, Human
  • Humans
  • Immunization, Secondary*
  • Male
  • Post-Exposure Prophylaxis*
  • Prospective Studies
  • Surveys and Questionnaires
  • Vaccine Potency

Substances

  • Chickenpox Vaccine